The Hallmarks of Cancer from a Redox Perspective
Publication: Antioxidants & Redox Signaling
Volume 25, Issue Number 6
Abstract
Significance: For a healthy cell to turn into a cancer cell and grow out to become a tumor, it needs to undergo a series of complex changes and acquire certain traits, summarized as “The Hallmarks of Cancer.” These hallmarks can all be regarded as the result of altered signal transduction cascades and an understanding of these cascades is essential for cancer treatment. Recent Advances: Redox signaling is a long overlooked form of signal transduction that proceeds through the reversible oxidation of cysteines in proteins and that uses hydrogen peroxide as a second messenger. Critical Issues: In this article, we provide examples that show that redox signaling is involved in the regulation of proteins and signaling cascades that play roles in every hallmark of cancer. Future Directions: An understanding of how redox signaling and “classical” signal transduction are intertwined could hold promising strategies for cancer therapy in the future. Antioxid. Redox Signal. 25, 300–325.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Abate C, Patel L, Rauscher FJ 3rd, and Curran T. Redox regulation of fos and jun DNA-binding activity in vitro. Science 249: 1157–1161, 1990.
2.
Abbas T and Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9: 400–414, 2009.
3.
Adachi Y, Shibai Y, Mitsushita J, Shang WH, Hirose K, and Kamata T. Oncogenic Ras upregulates NADPH oxidase 1 gene expression through MEK-ERK-dependent phosphorylation of GATA-6. Oncogene 27: 4921–4932, 2008.
4.
Al-Shabrawey M, Bartoli M, El-Remessy AB, Platt DH, Matragoon S, Behzadian MA, Caldwell RW, and Caldwell RB. Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy. Am J Pathol 167: 599–607, 2005.
5.
Alberghina L and Gaglio D. Redox control of glutamine utilization in cancer. Cell Death Dis 5: e1561, 2014.
6.
Altomonte J, Richter A, Harbaran S, Suriawinata J, Nakae J, Thung SN, Meseck M, Accili D, and Dong H. Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice. Am J Physiol Endocrinol Metab 285: E718–E728, 2003.
7.
Anastasiou D, Poulogiannis G, Asara JM, Boxer MB, Jiang JK, Shen M, Bellinger G, Sasaki AT, Locasale JW, Auld DS, Thomas CJ, Vander Heiden MG, and Cantley LC. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 334: 1278–1283, 2011.
8.
Antico Arciuch VG, Galli S, Franco MC, Lam PY, Cadenas E, Carreras MC, and Poderoso JJ. Akt1 intramitochondrial cycling is a crucial step in the redox modulation of cell cycle progression. PLoS One 4: e7523, 2009.
9.
Arbiser JL, Petros J, Klafter R, Govindajaran B, McLaughlin ER, Brown LF, Cohen C, Moses M, Kilroy S, Arnold RS, and Lambeth JD. Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc Natl Acad Sci U S A 99: 715–720, 2002.
10.
Assaily W, Rubinger DA, Wheaton K, Lin Y, Ma W, Xuan W, Brown-Endres L, Tsuchihara K, Mak TW, and Benchimol S. ROS-mediated p53 induction of Lpin1 regulates fatty acid oxidation in response to nutritional stress. Mol Cell 44: 491–501, 2011.
11.
Bae I, Fan S, Meng Q, Rih JK, Kim HJ, Kang HJ, Xu J, Goldberg ID, Jaiswal AK, and Rosen EM. BRCA1 induces antioxidant gene expression and resistance to oxidative stress. Cancer Res 64: 7893–7909, 2004.
12.
Bardos JI and Ashcroft M. Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays 26: 262–269, 2004.
13.
Bensaad K, Cheung EC, and Vousden KH. Modulation of intracellular ROS levels by TIGAR controls autophagy. EMBO J 28: 3015–3026, 2009.
14.
Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, and Vousden KH. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126: 107–120, 2006.
15.
Berndtsson M, Hagg M, Panaretakis T, Havelka AM, Shoshan MC, and Linder S. Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J Cancer 120: 175–180, 2007.
16.
Birukova AA, Lee S, Starosta V, Wu T, Ho T, Kim J, Berliner JA, and Birukov KG. A role for VEGFR2 activation in endothelial responses caused by barrier disruptive OxPAPC concentrations. PLoS One 7: e30957, 2012.
17.
Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, Yang CS, Zheng SF, Gail M, Li GY, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 85: 1483–1492, 1993.
18.
Bochkov VN, Philippova M, Oskolkova O, Kadl A, Furnkranz A, Karabeg E, Afonyushkin T, Gruber F, Breuss J, Minchenko A, Mechtcheriakova D, Hohensinner P, Rychli K, Wojta J, Resink T, Erne P, Binder BR, and Leitinger N. Oxidized phospholipids stimulate angiogenesis via autocrine mechanisms, implicating a novel role for lipid oxidation in the evolution of atherosclerotic lesions. Circ Res 99: 900–908, 2006.
19.
Boivin B, Zhang S, Arbiser JL, Zhang ZY, and Tonks NK. A modified cysteinyl-labeling assay reveals reversible oxidation of protein tyrosine phosphatases in angiomyolipoma cells. Proc Natl Acad Sci U S A 105: 9959–9964, 2008.
20.
Boroughs LK and DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol 17: 351–359, 2015.
21.
Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, and Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857–868, 1999.
22.
Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW, and Greenberg ME. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303: 2011–2015, 2004.
23.
Buchheit CL, Weigel KJ, and Schafer ZT. Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression. Nat Rev Cancer 14: 632–641, 2014.
24.
Burch PM and Heintz NH. Redox regulation of cell-cycle re-entry: cyclin D1 as a primary target for the mitogenic effects of reactive oxygen and nitrogen species. Antioxid Redox Signal 7: 741–751, 2005.
25.
Burhans WC and Heintz NH. The cell cycle is a redox cycle: linking phase-specific targets to cell fate. Free Radic Biol Med 47: 1282–1293, 2009.
26.
Burkhart DL and Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 8: 671–682, 2008.
27.
Buzek J, Latonen L, Kurki S, Peltonen K, and Laiho M. Redox state of tumor suppressor p53 regulates its sequence-specific DNA binding in DNA-damaged cells by cysteine 277. Nucleic Acids Res 30: 2340–2348, 2002.
28.
Cai T, Fassina G, Morini M, Aluigi MG, Masiello L, Fontanini G, D'Agostini F, De Flora S, Noonan DM, and Albini A. N-acetylcysteine inhibits endothelial cell invasion and angiogenesis. Lab Invest 79: 1151–1159, 1999.
29.
Cairns RA, Harris IS, and Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 11: 85–95, 2011.
30.
Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, and Schumacker PT. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci U S A 95: 11715–11720, 1998.
31.
Chaneton B and Gottlieb E. Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer. Trends Biochem Sci 37: 309–316, 2012.
32.
Chaneton B, Hillmann P, Zheng L, Martin AC, Maddocks OD, Chokkathukalam A, Coyle JE, Jankevics A, Holding FP, Vousden KH, Frezza C, O'Reilly M, and Gottlieb E. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 491: 458–462, 2012.
33.
Charitou P, Rodriguez-Colman M, Gerrits J, van Triest M, Groot Koerkamp M, Hornsveld M, Holstege F, Verhoeven-Duif NM, and Burgering BM. FOXOs support the metabolic requirements of normal and tumor cells by promoting IDH1 expression. EMBO Rep 16: 456–466, 2015.
34.
Chen C, Pore N, Behrooz A, Ismail-Beigi F, and Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 276: 9519–9525, 2001.
35.
Chen W, Sun Z, Wang XJ, Jiang T, Huang Z, Fang D, and Zhang DD. Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol Cell 34: 663–673, 2009.
36.
Cheung EC, Lee P, Ceteci F, Nixon C, Blyth K, Sansom OJ, and Vousden KH. Opposing effects of TIGAR- and RAC1-derived ROS on Wnt-driven proliferation in the mouse intestine. Genes Dev 30: 52–63, 2016.
37.
Childs BG, Baker DJ, Kirkland JL, Campisi J, and van Deursen JM. Senescence and apoptosis: dueling or complementary cell fates? EMBO Rep 15: 1139–1153, 2014.
38.
Cicchillitti L, Fasanaro P, Biglioli P, Capogrossi MC, and Martelli F. Oxidative stress induces protein phosphatase 2A-dependent dephosphorylation of the pocket proteins pRb, p107, and p130. J Biol Chem 278: 19509–19517, 2003.
39.
Colavitti R, Pani G, Bedogni B, Anzevino R, Borrello S, Waltenberger J, and Galeotti T. Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR. J Biol Chem 277: 3101–3108, 2002.
40.
Colotta F, Allavena P, Sica A, Garlanda C, and Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30: 1073–1081, 2009.
41.
Colussi C, Albertini MC, Coppola S, Rovidati S, Galli F, and Ghibelli L. H2O2-induced block of glycolysis as an active ADP-ribosylation reaction protecting cells from apoptosis. FASEB J 14: 2266–2276, 2000.
42.
Conklin KA. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. Integr Cancer Ther 4: 110–130, 2005.
43.
Contractor T and Harris CR. p53 negatively regulates transcription of the pyruvate dehydrogenase kinase Pdk2. Cancer Res 72: 560–567, 2012.
44.
Cosentino C, Grieco D, and Costanzo V. ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair. EMBO J 30: 546–555, 2011.
45.
D'Autreaux B and Toledano MB. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol 8: 813–824, 2007.
46.
Dansen TB and Burgering BM. Unravelling the tumor-suppressive functions of FOXO proteins. Trends Cell Biol 18: 421–429, 2008.
47.
Dansen TB, Smits LM, van Triest MH, de Keizer PL, van Leenen D, Koerkamp MG, Szypowska A, Meppelink A, Brenkman AB, Yodoi J, Holstege FC, and Burgering BM. Redox-sensitive cysteines bridge p300/CBP-mediated acetylation and FoxO4 activity. Nat Chem Biol 5: 664–672, 2009.
48.
Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, and Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231–241, 1997.
49.
Davison CA, Durbin SM, Thau MR, Zellmer VR, Chapman SE, Diener J, Wathen C, Leevy WM, and Schafer ZT. Antioxidant enzymes mediate survival of breast cancer cells deprived of extracellular matrix. Cancer Res 73: 3704–3715, 2013.
50.
Davison K, Cote S, Mader S, and Miller WH. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 17: 931–940, 2003.
51.
Day AM, Brown JD, Taylor SR, Rand JD, Morgan BA, and Veal EA. Inactivation of a peroxiredoxin by hydrogen peroxide is critical for thioredoxin-mediated repair of oxidized proteins and cell survival. Mol Cell 45: 398–408, 2012.
52.
de Lange T. How telomeres solve the end-protection problem. Science 326: 948–952, 2009.
53.
Debnath J, Mills KR, Collins NL, Reginato MJ, Muthuswamy SK, and Brugge JS. The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 111: 29–40, 2002.
54.
Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8: 705–713, 2008.
55.
Dick FA and Rubin SM. Molecular mechanisms underlying RB protein function. Nat Rev Mol Cell Biol 14: 297–306, 2013.
56.
Ditch S and Paull TT. The ATM protein kinase and cellular redox signaling: beyond the DNA damage response. Trends Biochem Sci 37: 15–22, 2012.
57.
Donate F, Juarez JC, Burnett ME, Manuia MM, Guan X, Shaw DE, Smith EL, Timucin C, Braunstein MJ, Batuman OA, and Mazar AP. Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224). Br J Cancer 98: 776–783, 2008.
58.
Eijkelenboom A and Burgering BM. FOXOs: signalling integrators for homeostasis maintenance. Nat Rev Mol Cell Biol 14: 83–97, 2013.
59.
Eijkelenboom A, Mokry M, de Wit E, Smits LM, Polderman PE, van Triest MH, van Boxtel R, Schulze A, de Laat W, Cuppen E, and Burgering BM. Genome-wide analysis of FOXO3 mediated transcription regulation through RNA polymerase II profiling. Mol Syst Biol 9: 638, 2013.
60.
Eijkelenboom A, Mokry M, Smits LM, Nieuwenhuis EE, and Burgering BM. FOXO3 selectively amplifies enhancer activity to establish target gene regulation. Cell Rep 5: 1664–1678, 2013.
61.
Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, and Thompson CB. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64: 3892–3899, 2004.
62.
Ema M, Hirota K, Mimura J, Abe H, Yodoi J, Sogawa K, Poellinger L, and Fujii-Kuriyama Y. Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J 18: 1905–1914, 1999.
63.
Engel RH and Evens AM. Oxidative stress and apoptosis: a new treatment paradigm in cancer. Front Biosci 11: 300–312, 2006.
64.
Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, and Ratcliffe PJ. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43–54, 2001.
65.
Essers MA, Weijzen S, de Vries-Smits AM, Saarloos I, de Ruiter ND, Bos JL, and Burgering BM. FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. EMBO J 23: 4802–4812, 2004.
66.
Firth JD, Ebert BL, and Ratcliffe PJ. Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements. J Biol Chem 270: 21021–21027, 1995.
67.
Fisher AB. Redox signaling across cell membranes. Antioxid Redox Signal 11: 1349–1356, 2009.
68.
Franco R and Cidlowski JA. Apoptosis and glutathione: beyond an antioxidant. Cell Death Differ 16: 1303–1314, 2009.
69.
Fuchs-Tarlovsky V. Role of antioxidants in cancer therapy. Nutrition 29: 15–21, 2013.
70.
Fujikawa M, Katagiri T, Tugores A, Nakamura Y, and Ishikawa F. ESE-3, an Ets family transcription factor, is up-regulated in cellular senescence. Cancer Sci 98: 1468–1475, 2007.
71.
Gad H, Koolmeister T, Jemth AS, Eshtad S, Jacques SA, Strom CE, Svensson LM, Schultz N, Lundback T, Einarsdottir BO, Saleh A, Gokturk C, Baranczewski P, Svensson R, Berntsson RP, Gustafsson R, Stromberg K, Sanjiv K, Jacques-Cordonnier MC, Desroses M, Gustavsson AL, Olofsson R, Johansson F, Homan EJ, Loseva O, Brautigam L, Johansson L, Hoglund A, Hagenkort A, Pham T, Altun M, Gaugaz FZ, Vikingsson S, Evers B, Henriksson M, Vallin KS, Wallner OA, Hammarstrom LG, Wiita E, Almlof I, Kalderen C, Axelsson H, Djureinovic T, Puigvert JC, Haggblad M, Jeppsson F, Martens U, Lundin C, Lundgren B, Granelli I, Jensen AJ, Artursson P, Nilsson JA, Stenmark P, Scobie M, Berglund UW, and Helleday T. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature 508: 215–221, 2014.
72.
Gaglio D, Metallo CM, Gameiro PA, Hiller K, Danna LS, Balestrieri C, Alberghina L, Stephanopoulos G, and Chiaradonna F. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol 7: 523, 2011.
73.
Gallogly MM and Mieyal JJ. Mechanisms of reversible protein glutathionylation in redox signaling and oxidative stress. Curr Opin Pharmacol 7: 381–391, 2007.
74.
Gardai SJ, Hildeman DA, Frankel SK, Whitlock BB, Frasch SC, Borregaard N, Marrack P, Bratton DL, and Henson PM. Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. J Biol Chem 279: 21085–21095, 2004.
75.
Garrido-Urbani S, Jemelin S, Deffert C, Carnesecchi S, Basset O, Szyndralewiez C, Heitz F, Page P, Montet X, Michalik L, Arbiser J, Ruegg C, Krause KH, and Imhof BA. Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARalpha mediated mechanism. PLoS One 6: e14665, 2011.
76.
Giannoni E, Buricchi F, Grimaldi G, Parri M, Cialdai F, Taddei ML, Raugei G, Ramponi G, and Chiarugi P. Redox regulation of anoikis: reactive oxygen species as essential mediators of cell survival. Cell Death Differ 15: 867–878, 2008.
77.
Giannoni E, Buricchi F, Raugei G, Ramponi G, and Chiarugi P. Intracellular reactive oxygen species activate Src tyrosine kinase during cell adhesion and anchorage-dependent cell growth. Mol Cell Biol 25: 6391–6403, 2005.
78.
Giannoni E, Fiaschi T, Ramponi G, and Chiarugi P. Redox regulation of anoikis resistance of metastatic prostate cancer cells: key role for Src and EGFR-mediated pro-survival signals. Oncogene 28: 2074–2086, 2009.
79.
Giannoni E, Parri M, and Chiarugi P. EMT and oxidative stress: a bidirectional interplay affecting tumor malignancy. Antioxid Redox Signal 16: 1248–1263, 2012.
80.
Giorgio M, Migliaccio E, Orsini F, Paolucci D, Moroni M, Contursi C, Pelliccia G, Luzi L, Minucci S, Marcaccio M, Pinton P, Rizzuto R, Bernardi P, Paolucci F, and Pelicci PG. Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell 122: 221–233, 2005.
81.
Glasauer A and Chandel NS. Targeting antioxidants for cancer therapy. Biochem Pharmacol 92: 90–101, 2014.
82.
Gorrini C, Baniasadi PS, Harris IS, Silvester J, Inoue S, Snow B, Joshi PA, Wakeham A, Molyneux SD, Martin B, Bouwman P, Cescon DW, Elia AJ, Winterton-Perks Z, Cruickshank J, Brenner D, Tseng A, Musgrave M, Berman HK, Khokha R, Jonkers J, Mak TW, and Gauthier ML. BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. J Exp Med 210: 1529–1544, 2013.
83.
Gorrini C, Harris IS, and Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 12: 931–947, 2013.
84.
Gossage L, Eisen T, and Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer 15: 55–64, 2015.
85.
Gout PW, Buckley AR, Simms CR, and Bruchovsky N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia 15: 1633–1640, 2001.
86.
Greer EL, Oskoui PR, Banko MR, Maniar JM, Gygi MP, Gygi SP, and Brunet A. The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. J Biol Chem 282: 30107–30119, 2007.
87.
Griffith OW. Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. J Biol Chem 257: 13704–13712, 1982.
88.
Grivennikov SI, Greten FR, and Karin M. Immunity, inflammation, and cancer. Cell 140: 883–899, 2010.
89.
Guan J, Lo M, Dockery P, Mahon S, Karp CM, Buckley AR, Lam S, Gout PW, and Wang YZ. The xc- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine. Cancer Chemother Pharmacol 64: 463–472, 2009.
90.
Guo Z, Kozlov S, Lavin MF, Person MD, and Paull TT. ATM activation by oxidative stress. Science 330: 517–521, 2010.
91.
Hainaut P and Milner J. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res 53: 4469–4473, 1993.
92.
Hanahan D and Weinberg RA. The hallmarks of cancer. Cell 100: 57–70, 2000.
93.
Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell 144: 646–674, 2011.
94.
Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 11: 298–300, 1956.
95.
Hayflick L. Living forever and dying in the attempt. Exp Gerontol 38: 1231–1241, 2003.
96.
Hekimi S, Lapointe J, and Wen Y. Taking a “good” look at free radicals in the aging process. Trends Cell Biol 21: 569–576, 2011.
97.
Held JM, Danielson SR, Behring JB, Atsriku C, Britton DJ, Puckett RL, Schilling B, Campisi J, Benz CC, and Gibson BW. Targeted quantitation of site-specific cysteine oxidation in endogenous proteins using a differential alkylation and multiple reaction monitoring mass spectrometry approach. Mol Cell Proteomics 9: 1400–1410, 2010.
98.
Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 411: 366–374, 2001.
99.
Holmstrom KM and Finkel T. Cellular mechanisms and physiological consequences of redox-dependent signalling. Nat Rev Mol Cell Biol 15: 411–421, 2014.
100.
Hornsveld M, Tenhagen M, van de Ven RA, Smits AM, van Triest MH, van Amersfoort M, Kloet DE, Dansen TB, Burgering BM, and Derksen PW. Restraining FOXO3-dependent transcriptional BMF activation underpins tumour growth and metastasis of E-cadherin-negative breast cancer. Cell Death Differ 2016 [Epub ahead of print];.
101.
Hu W, Zhang C, Wu R, Sun Y, Levine A, and Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci U S A 107: 7455–7460, 2010.
102.
Huang LE, Arany Z, Livingston DM, and Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 271: 32253–32259, 1996.
103.
Huang X, Begley M, Morgenstern KA, Gu Y, Rose P, Zhao H, and Zhu X. Crystal structure of an inactive Akt2 kinase domain. Structure 11: 21–30, 2003.
104.
Hurst R, Hooper L, Norat T, Lau R, Aune D, Greenwood DC, Vieira R, Collings R, Harvey LJ, Sterne JA, Beynon R, Savovic J, and Fairweather-Tait SJ. Selenium and prostate cancer: systematic review and meta-analysis. Am J Clin Nutr 96: 111–122, 2012.
105.
Hwang PM, Bunz F, Yu J, Rago C, Chan TA, Murphy MP, Kelso GF, Smith RA, Kinzler KW, and Vogelstein B. Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nat Med 7: 1111–1117, 2001.
106.
Indran IR, Hande MP, and Pervaiz S. hTERT overexpression alleviates intracellular ROS production, improves mitochondrial function, and inhibits ROS-mediated apoptosis in cancer cells. Cancer Res 71: 266–276, 2011.
107.
Jackson SP and Bartek J. The DNA-damage response in human biology and disease. Nature 461: 1071–1078, 2009.
108.
Jacobs JJ, Kieboom K, Marino S, DePinho RA, and van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397: 164–168, 1999.
109.
Jarvis RM, Hughes SM, and Ledgerwood EC. Peroxiredoxin 1 functions as a signal peroxidase to receive, transduce, and transmit peroxide signals in mammalian cells. Free Radic Biol Med 53: 1522–1530, 2012.
110.
Jayaraman L, Murthy KG, Zhu C, Curran T, Xanthoudakis S, and Prives C. Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev 11: 558–570, 1997.
111.
Jiang F, Zhang Y, and Dusting GJ. NADPH oxidase-mediated redox signaling: roles in cellular stress response, stress tolerance, and tissue repair. Pharmacol Rev 63: 218–242, 2011.
112.
Jiang P, Du W, Wang X, Mancuso A, Gao X, Wu M, and Yang X. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol 13: 310–316, 2011.
113.
Jones DP and Sies H. The Redox Code. Antioxid Redox Signal 23: 734–746, 2015.
114.
Juin P, Geneste O, Gautier F, Depil S, and Campone M. Decoding and unlocking the BCL-2 dependency of cancer cells. Nat Rev Cancer 13: 455–465, 2013.
115.
Karisch R, Fernandez M, Taylor P, Virtanen C, St-Germain JR, Jin LL, Harris IS, Mori J, Mak TW, Senis YA, Ostman A, Moran MF, and Neel BG. Global proteomic assessment of the classical protein-tyrosine phosphatome and “Redoxome”. Cell 146: 826–840, 2011.
116.
Kawauchi K, Araki K, Tobiume K, and Tanaka N. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol 10: 611–618, 2008.
117.
Kelley MR, Georgiadis MM, and Fishel ML. APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1. Curr Mol Pharmacol 5: 36–53, 2012.
118.
Khanday FA, Santhanam L, Kasuno K, Yamamori T, Naqvi A, Dericco J, Bugayenko A, Mattagajasingh I, Disanza A, Scita G, and Irani K. Sos-mediated activation of rac1 by p66shc. J Cell Biol 172: 817–822, 2006.
119.
Khanday FA, Yamamori T, Mattagajasingh I, Zhang Z, Bugayenko A, Naqvi A, Santhanam L, Nabi N, Kasuno K, Day BW, and Irani K. Rac1 leads to phosphorylation-dependent increase in stability of the p66shc adaptor protein: role in Rac1-induced oxidative stress. Mol Biol Cell 17: 122–129, 2006.
120.
Kim HR, Roe JS, Lee JE, Cho EJ, and Youn HD. p53 regulates glucose metabolism by miR-34a. Biochem Biophys Res Commun 437: 225–231, 2013.
121.
Kim JW, Tchernyshyov I, Semenza GL, and Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3: 177–185, 2006.
122.
Kim R, Emi M, and Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 121: 1–14, 2007.
123.
Kim YM, Kim KE, Koh GY, Ho YS, and Lee KJ. Hydrogen peroxide produced by angiopoietin-1 mediates angiogenesis. Cancer Res 66: 6167–6174, 2006.
124.
Kim YW and Byzova TV. Oxidative stress in angiogenesis and vascular disease. Blood 123: 625–631, 2014.
125.
Kitamura T, Qian BZ, and Pollard JW. Immune cell promotion of metastasis. Nat Rev Immunol 15: 73–86, 2015.
126.
Klamt F, Zdanov S, Levine RL, Pariser A, Zhang Y, Zhang B, Yu LR, Veenstra TD, and Shacter E. Oxidant-induced apoptosis is mediated by oxidation of the actin-regulatory protein cofilin. Nat Cell Biol 11: 1241–1246, 2009.
127.
Klein EA, Thompson IM Jr., Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr., and Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306: 1549–1556, 2011.
128.
Klotz LO, Sanchez-Ramos C, Prieto-Arroyo I, Urbanek P, Steinbrenner H, and Monsalve M. Redox regulation of FoxO transcription factors. Redox Biol 6: 51–72, 2015.
129.
Konior A, Schramm A, Czesnikiewicz-Guzik M, and Guzik TJ. NADPH oxidases in vascular pathology. Antioxid Redox Signal 20: 2794–2814, 2014.
130.
Kops GJ, de Ruiter ND, De Vries-Smits AM, Powell DR, Bos JL, and Burgering BM. Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 398: 630–634, 1999.
131.
Kousteni S. FoxO1, the transcriptional chief of staff of energy metabolism. Bone 50: 437–443, 2012.
132.
Kranc KR, Schepers H, Rodrigues NP, Bamforth S, Villadsen E, Ferry H, Bouriez-Jones T, Sigvardsson M, Bhattacharya S, Jacobsen SE, and Enver T. Cited2 is an essential regulator of adult hematopoietic stem cells. Cell Stem Cell 5: 659–665, 2009.
133.
Kruiswijk F, Labuschagne CF, and Vousden KH. p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat Rev Mol Cell Biol 16: 393–405, 2015.
134.
Kwon J, Lee SR, Yang KS, Ahn Y, Kim YJ, Stadtman ER, and Rhee SG. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc Natl Acad Sci U S A 101: 16419–16424, 2004.
135.
Labuschagne CF, van den Broek NJ, Mackay GM, Vousden KH, and Maddocks OD. Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells. Cell Rep 7: 1248–1258, 2014.
136.
Lamouille S, Xu J, and Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15: 178–196, 2014.
137.
Lazzerini-Denchi E and Sfeir A. Stop pulling my strings—what telomeres taught us about the DNA damage response. Nat Rev Mol Cell Biol 17: 364–378, 2016.
138.
Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J, Tsukamoto T, Rojas CJ, Slusher BS, Zhang H, Zimmerman LJ, Liebler DC, Slebos RJ, Lorkiewicz PK, Higashi RM, Fan TW, and Dang CV. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab 15: 110–121, 2012.
139.
Le Page F, Randrianarison V, Marot D, Cabannes J, Perricaudet M, Feunteun J, and Sarasin A. BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine lesion in human cells. Cancer Res 60: 5548–5552, 2000.
140.
Lee SR, Yang KS, Kwon J, Lee C, Jeong W, and Rhee SG. Reversible inactivation of the tumor suppressor PTEN by H2O2. J Biol Chem 277: 20336–20342, 2002.
141.
Lennicke C, Rahn J, Heimer N, Lichtenfels R, Wessjohann LA, and Seliger B. Redox proteomics: methods for the identification and enrichment of redox-modified proteins and their applications. Proteomics 16: 197–213, 2016.
142.
Leonard SE, Reddie KG, and Carroll KS. Mining the thiol proteome for sulfenic acid modifications reveals new targets for oxidation in cells. ACS Chem Biol 4: 783–799, 2009.
143.
Leslie NR, Batty IH, Maccario H, Davidson L, and Downes CP. Understanding PTEN regulation: PIP2, polarity and protein stability. Oncogene 27: 5464–5476, 2008.
144.
Leslie NR, Bennett D, Lindsay YE, Stewart H, Gray A, and Downes CP. Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J 22: 5501–5510, 2003.
145.
Leung CT and Brugge JS. Outgrowth of single oncogene-expressing cells from suppressive epithelial environments. Nature 482: 410–413, 2012.
146.
Lieber MR. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem 79: 181–211, 2010.
147.
Liu B, Chen Y, and St Clair DK. ROS and p53: a versatile partnership. Free Radic Biol Med 44: 1529–1535, 2008.
148.
Locasale JW. Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer 13: 572–583, 2013.
149.
Lopez-Otin C, Blasco MA, Partridge L, Serrano M, and Kroemer G. The hallmarks of aging. Cell 153: 1194–1217, 2013.
150.
Luanpitpong S, Chanvorachote P, Stehlik C, Tse W, Callery PS, Wang L, and Rojanasakul Y. Regulation of apoptosis by Bcl-2 cysteine oxidation in human lung epithelial cells. Mol Biol Cell 24: 858–869, 2013.
151.
Luo M, He H, Kelley MR, and Georgiadis MM. Redox regulation of DNA repair: implications for human health and cancer therapeutic development. Antioxid Redox Signal 12: 1247–1269, 2010.
152.
Macip S, Igarashi M, Berggren P, Yu J, Lee SW, and Aaronson SA. Influence of induced reactive oxygen species in p53-mediated cell fate decisions. Mol Cell Biol 23: 8576–8585, 2003.
153.
Macleod KF. The role of the RB tumour suppressor pathway in oxidative stress responses in the haematopoietic system. Nat Rev Cancer 8: 769–781, 2008.
154.
Maddocks OD, Berkers CR, Mason SM, Zheng L, Blyth K, Gottlieb E, and Vousden KH. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 493: 542–546, 2013.
155.
Madlener S, Strobel T, Vose S, Saydam O, Price BD, Demple B, and Saydam N. Essential role for mammalian apurinic/apyrimidinic (AP) endonuclease Ape1/Ref-1 in telomere maintenance. Proc Natl Acad Sci U S A 110: 17844–17849, 2013.
156.
Maeda H, Hori S, Ohizumi H, Segawa T, Kakehi Y, Ogawa O, and Kakizuka A. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine. Cell Death Differ 11: 737–746, 2004.
157.
Magenta A, Fasanaro P, Romani S, Di Stefano V, Capogrossi MC, and Martelli F. Protein phosphatase 2A subunit PR70 interacts with pRb and mediates its dephosphorylation. Mol Cell Biol 28: 873–882, 2008.
158.
Mahadev K, Motoshima H, Wu X, Ruddy JM, Arnold RS, Cheng G, Lambeth JD, and Goldstein BJ. The NAD(P)H oxidase homolog Nox4 modulates insulin-stimulated generation of H2O2 and plays an integral role in insulin signal transduction. Mol Cell Biol 24: 1844–1854, 2004.
159.
Maillet A and Pervaiz S. Redox regulation of p53, redox effectors regulated by p53: a subtle balance. Antioxid Redox Signal 16: 1285–1294, 2012.
160.
Mailleux AA, Overholtzer M, Schmelzle T, Bouillet P, Strasser A, and Brugge JS. BIM regulates apoptosis during mammary ductal morphogenesis, and its absence reveals alternative cell death mechanisms. Dev Cell 12: 221–234, 2007.
161.
Maltepe E, Schmidt JV, Baunoch D, Bradfield CA, and Simon MC. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 386: 403–407, 1997.
162.
Marani M, Hancock D, Lopes R, Tenev T, Downward J, and Lemoine NR. Role of Bim in the survival pathway induced by Raf in epithelial cells. Oncogene 23: 2431–2441, 2004.
163.
Marzano C, Gandin V, Folda A, Scutari G, Bindoli A, and Rigobello MP. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic Biol Med 42: 872–881, 2007.
164.
Mathupala SP, Heese C, and Pedersen PL. Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53. J Biol Chem 272: 22776–22780, 1997.
165.
Mathupala SP, Rempel A, and Pedersen PL. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 276: 43407–43412, 2001.
166.
Matsuzawa A and Ichijo H. Redox control of cell fate by MAP kinase: physiological roles of ASK1-MAP kinase pathway in stress signaling. Biochim Biophys Acta 1780: 1325–1336, 2008.
167.
Medema RH, Kops GJ, Bos JL, and Burgering BM. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404: 782–787, 2000.
168.
Minchenko A, Leshchinsky I, Opentanova I, Sang N, Srinivas V, Armstead V, and Caro J. Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect. J Biol Chem 277: 6183–6187, 2002.
169.
Monte M, Davel LE, and de Lustig ES. Inhibition of lymphocyte-induced angiogenesis by free radical scavengers. Free Radic Biol Med 17: 259–266, 1994.
170.
Monte M, Davel LE, and Sacerdote de Lustig E. Hydrogen peroxide is involved in lymphocyte activation mechanisms to induce angiogenesis. Eur J Cancer 33: 676–682, 1997.
171.
Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W, Bultsma Y, McBurney M, and Guarente L. Mammalian SIRT1 represses forkhead transcription factors. Cell 116: 551–563, 2004.
172.
Murata H, Ihara Y, Nakamura H, Yodoi J, Sumikawa K, and Kondo T. Glutaredoxin exerts an antiapoptotic effect by regulating the redox state of Akt. J Biol Chem 278: 50226–50233, 2003.
173.
Murphy MP. How mitochondria produce reactive oxygen species. Biochem J 417: 1–13, 2009.
174.
Murphy MP. Mitochondrial thiols in antioxidant protection and redox signaling: distinct roles for glutathionylation and other thiol modifications. Antioxid Redox Signal 16: 476–495, 2012.
175.
Nakae J, Kitamura T, Silver DL, and Accili D. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J Clin Invest 108: 1359–1367, 2001.
176.
Nakajima H, Amano W, Fujita A, Fukuhara A, Azuma YT, Hata F, Inui T, and Takeuchi T. The active site cysteine of the proapoptotic protein glyceraldehyde-3-phosphate dehydrogenase is essential in oxidative stress-induced aggregation and cell death. J Biol Chem 282: 26562–26574, 2007.
177.
Nogueira V, Park Y, Chen CC, Xu PZ, Chen ML, Tonic I, Unterman T, and Hay N. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 14: 458–470, 2008.
178.
Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, Miao L, Tothova Z, Horner JW, Carrasco DR, Jiang S, Gilliland DG, Chin L, Wong WH, Castrillon DH, and DePinho RA. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 128: 309–323, 2007.
179.
Papandreou I, Cairns RA, Fontana L, Lim AL, and Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3: 187–197, 2006.
180.
Park HS, Park D, and Bae YS. Molecular interaction of NADPH oxidase 1 with betaPix and Nox Organizer 1. Biochem Biophys Res Commun 339: 985–990, 2006.
181.
Parks D, Bolinger R, and Mann K. Redox state regulates binding of p53 to sequence-specific DNA, but not to non-specific or mismatched DNA. Nucleic Acids Res 25: 1289–1295, 1997.
182.
Peralta D, Bronowska AK, Morgan B, Doka E, Van Laer K, Nagy P, Grater F, and Dick TP. A proton relay enhances H2O2 sensitivity of GAPDH to facilitate metabolic adaptation. Nat Chem Biol 11: 156–163, 2015.
183.
Polimeni M, Voena C, Kopecka J, Riganti C, Pescarmona G, Bosia A, and Ghigo D. Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity. Biochem J 439: 141–149, 2011.
184.
Polyak K, Xia Y, Zweier JL, Kinzler KW, and Vogelstein B. A model for p53-induced apoptosis. Nature 389: 300–305, 1997.
185.
Putker M, Madl T, Vos HR, de Ruiter H, Visscher M, van den Berg MC, Kaplan M, Korswagen HC, Boelens R, Vermeulen M, Burgering BM, and Dansen TB. Redox-dependent control of FOXO/DAF-16 by transportin-1. Mol Cell 49: 730–742, 2013.
186.
Putker M, Vos HR, van Dorenmalen K, de Ruiter H, Duran AG, Snel B, Burgering BM, Vermeulen M, and Dansen TB. Evolutionary acquisition of cysteines determines FOXO paralog-specific redox signaling. Antioxid Redox Signal 22: 15–28, 2015.
187.
Qiao YL, Dawsey SM, Kamangar F, Fan JH, Abnet CC, Sun XD, Johnson LL, Gail MH, Dong ZW, Yu B, Mark SD, and Taylor PR. Total and cancer mortality after supplementation with vitamins and minerals: follow-up of the Linxian General Population Nutrition Intervention Trial. J Natl Cancer Inst 101: 507–518, 2009.
188.
Rainwater R, Parks D, Anderson ME, Tegtmeyer P, and Mann K. Role of cysteine residues in regulation of p53 function. Mol Cell Biol 15: 3892–3903, 1995.
189.
Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, Tolliday NJ, Golub TR, Carr SA, Shamji AF, Stern AM, Mandinova A, Schreiber SL, and Lee SW. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475: 231–234, 2011.
190.
Reuter S, Gupta SC, Chaturvedi MM, and Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 49: 1603–1616, 2010.
191.
Rey S and Semenza GL. Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. Cardiovasc Res 86: 236–242, 2010.
192.
Richman EL and Chan JM. Selenium and prostate cancer: the puzzle isn't finished yet. Am J Clin Nutr 96: 1–2, 2012.
193.
Richter T and Proctor C. The role of intracellular peroxide levels on the development and maintenance of telomere-dependent senescence. Exp Gerontol 42: 1043–1052, 2007.
194.
Rudolph J and Stokoe D. Selective inhibition of mutant Ras protein through covalent binding. Angew Chem Int Ed Engl 53: 3777–3779, 2014.
195.
Ruiz-Lozano P, Hixon ML, Wagner MW, Flores AI, Ikawa S, Baldwin AS Jr., Chien KR, and Gualberto A. p53 is a transcriptional activator of the muscle-specific phosphoglycerate mutase gene and contributes in vivo to the control of its cardiac expression. Cell Growth Differ 10: 295–306, 1999.
196.
Russo MT, Blasi MF, Chiera F, Fortini P, Degan P, Macpherson P, Furuichi M, Nakabeppu Y, Karran P, Aquilina G, and Bignami M. The oxidized deoxynucleoside triphosphate pool is a significant contributor to genetic instability in mismatch repair-deficient cells. Mol Cell Biol 24: 465–474, 2004.
197.
Ryter SW, Kim HP, Hoetzel A, Park JW, Nakahira K, Wang X, and Choi AM. Mechanisms of cell death in oxidative stress. Antioxid Redox Signal 9: 49–89, 2007.
198.
Ryu CS, Kwak HC, Lee JY, Oh SJ, Phuong NT, Kang KW, and Kim SK. Elevation of cysteine consumption in tamoxifen-resistant MCF-7 cells. Biochem Pharmacol 85: 197–206, 2013.
199.
Sabharwal SS and Schumacker PT. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles’ heel? Nat Rev Cancer 14: 709–721, 2014.
200.
Saha T, Rih JK, Roy R, Ballal R, and Rosen EM. Transcriptional regulation of the base excision repair pathway by BRCA1. J Biol Chem 285: 19092–19105, 2010.
201.
San Filippo J, Sung P, and Klein H. Mechanism of eukaryotic homologous recombination. Annu Rev Biochem 77: 229–257, 2008.
202.
Sanchez-Macedo N, Feng J, Faubert B, Chang N, Elia A, Rushing EJ, Tsuchihara K, Bungard D, Berger SL, Jones RG, Mak TW, and Zaugg K. Depletion of the novel p53-target gene carnitine palmitoyltransferase 1C delays tumor growth in the neurofibromatosis type I tumor model. Cell Death Differ 20: 659–668, 2013.
203.
Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY, Gao S, Puigserver P, and Brugge JS. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 461: 109–113, 2009.
204.
Schmelzle T, Mailleux AA, Overholtzer M, Carroll JS, Solimini NL, Lightcap ES, Veiby OP, and Brugge JS. Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis. Proc Natl Acad Sci U S A 104: 3787–3792, 2007.
205.
Semenza GL. Molecular mechanisms mediating metastasis of hypoxic breast cancer cells. Trends Mol Med 18: 534–543, 2012.
206.
Semenza GL. Oxygen sensing, homeostasis, and disease. N Engl J Med 365: 537–547, 2011.
207.
Semenza GL, Roth PH, Fang HM, and Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 269: 23757–23763, 1994.
208.
Serrano M, Lin AW, McCurrach ME, Beach D, and Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88: 593–602, 1997.
209.
Shao Y and Aplin AE. ERK2 phosphorylation of serine 77 regulates Bmf pro-apoptotic activity. Cell Death Dis 3: e253, 2012.
210.
Shatrov VA, Sumbayev VV, Zhou J, and Brune B. Oxidized low-density lipoprotein (oxLDL) triggers hypoxia-inducible factor-1alpha (HIF-1alpha) accumulation via redox-dependent mechanisms. Blood 101: 4847–4849, 2003.
211.
Shiloh Y and Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol 14: 197–210, 2013.
212.
Sobhakumari A, Love-Homan L, Fletcher EV, Martin SM, Parsons AD, Spitz DR, Knudson CM, and Simons AL. Susceptibility of human head and neck cancer cells to combined inhibition of glutathione and thioredoxin metabolism. PLoS One 7: e48175, 2012.
213.
Sobotta MC, Liou W, Stocker S, Talwar D, Oehler M, Ruppert T, Scharf AN, and Dick TP. Peroxiredoxin-2 and STAT3 form a redox relay for H2O2 signaling. Nat Chem Biol 11: 64–70, 2015.
214.
Somwar R, Erdjument-Bromage H, Larsson E, Shum D, Lockwood WW, Yang G, Sander C, Ouerfelli O, Tempst PJ, Djaballah H, and Varmus HE. Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines. Proc Natl Acad Sci U S A 108: 16375–16380, 2011.
215.
Sporn MB and Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer 12: 564–571, 2012.
216.
Stahl M, Dijkers PF, Kops GJ, Lens SM, Coffer PJ, Burgering BM, and Medema RH. The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J Immunol 168: 5024–5031, 2002.
217.
Stein GH, Drullinger LF, Soulard A, and Dulic V. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol Cell Biol 19: 2109–2117, 1999.
218.
Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell GR, Yates LR, Papaemmanuil E, Beare D, Butler A, Cheverton A, Gamble J, Hinton J, Jia M, Jayakumar A, Jones D, Latimer C, Lau KW, McLaren S, McBride DJ, Menzies A, Mudie L, Raine K, Rad R, Chapman MS, Teague J, Easton D, Langerod A, Oslo Breast Cancer C, Lee MT, Shen CY, Tee BT, Huimin BW, Broeks A, Vargas AC, Turashvili G, Martens J, Fatima A, Miron P, Chin SF, Thomas G, Boyault S, Mariani O, Lakhani SR, van de Vijver M, van ‘t Veer L, Foekens J, Desmedt C, Sotiriou C, Tutt A, Caldas C, Reis-Filho JS, Aparicio SA, Salomon AV, Borresen-Dale AL, Richardson AL, Campbell PJ, Futreal PA, and Stratton MR. The landscape of cancer genes and mutational processes in breast cancer. Nature 486: 400–404, 2012.
219.
Strasser A, Cory S, and Adams JM. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J 30: 3667–3683, 2011.
220.
Strasser A, Jost PJ, and Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity 30: 180–192, 2009.
221.
Sun XZ, Vinci C, Makmura L, Han S, Tran D, Nguyen J, Hamann M, Grazziani S, Sheppard S, Gutova M, Zhou F, Thomas J, and Momand J. Formation of disulfide bond in p53 correlates with inhibition of DNA binding and tetramerization. Antioxid Redox Signal 5: 655–665, 2003.
222.
Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S, Lokshin M, Hosokawa H, Nakayama T, Suzuki Y, Sugano S, Sato E, Nagao T, Yokote K, Tatsuno I, and Prives C. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci U S A 107: 7461–7466, 2010.
223.
Sweeney C, Liu G, Yiannoutsos C, Kolesar J, Horvath D, Staab MJ, Fife K, Armstrong V, Treston A, Sidor C, and Wilding G. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res 11: 6625–6633, 2005.
224.
Swenberg JA, Lu K, Moeller BC, Gao L, Upton PB, Nakamura J, and Starr TB. Endogenous versus exogenous DNA adducts: their role in carcinogenesis, epidemiology, and risk assessment. Toxicol Sci 120 Suppl 1: S130–S145, 2011.
225.
Tai DJ, Jin WS, Wu CS, Si HW, Cao XD, Guo AJ, and Chang JC. Changes in intracellular redox status influence multidrug resistance in gastric adenocarcinoma cells. Exp Ther Med 4: 291–296, 2012.
226.
Teng MW, Swann JB, Koebel CM, Schreiber RD, and Smyth MJ. Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol 84: 988–993, 2008.
227.
Tennant DA, Durán RV, and Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 10: 267–277, 2010.
228.
Timmerman LA, Holton T, Yuneva M, Louie RJ, Padro M, Daemen A, Hu M, Chan DA, Ethier SP, van ‘t Veer LJ, Polyak K, McCormick F, and Gray JW. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 24: 450–465, 2013.
229.
Tojo T, Ushio-Fukai M, Yamaoka-Tojo M, Ikeda S, Patrushev N, and Alexander RW. Role of gp91phox (Nox2)-containing NAD(P)H oxidase in angiogenesis in response to hindlimb ischemia. Circulation 111: 2347–2355, 2005.
230.
Townsend DM, He L, Hutchens S, Garrett TE, Pazoles CJ, and Tew KD. NOV-002, a glutathione disulfide mimetic, as a modulator of cellular redox balance. Cancer Res 68: 2870–2877, 2008.
231.
Trachootham D, Alexandre J, and Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8: 579–591, 2009.
232.
Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J, and Huang P. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10: 241–252, 2006.
233.
Trinei M, Giorgio M, Cicalese A, Barozzi S, Ventura A, Migliaccio E, Milia E, Padura IM, Raker VA, Maccarana M, Petronilli V, Minucci S, Bernardi P, Lanfrancone L, and Pelicci PG. A p53-p66Shc signalling pathway controls intracellular redox status, levels of oxidation-damaged DNA and oxidative stress-induced apoptosis. Oncogene 21: 3872–3878, 2002.
234.
Tsai KL, Sun YJ, Huang CY, Yang JY, Hung MC, and Hsiao CD. Crystal structure of the human FOXO3a-DBD/DNA complex suggests the effects of post-translational modification. Nucleic Acids Res 35: 6984–6994, 2007.
235.
Ullah MS, Davies AJ, and Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem 281: 9030–9037, 2006.
236.
van den Heuvel S and Dyson NJ. Conserved functions of the pRB and E2F families. Nat Rev Mol Cell Biol 9: 713–724, 2008.
237.
van der Horst A and Burgering BM. Stressing the role of FoxO proteins in lifespan and disease. Nat Rev Mol Cell Biol 8: 440–450, 2007.
238.
van der Horst A, Tertoolen LG, de Vries-Smits LM, Frye RA, Medema RH, and Burgering BM. FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1). J Biol Chem 279: 28873–28879, 2004.
239.
van der Vos KE, Eliasson P, Proikas-Cezanne T, Vervoort SJ, van Boxtel R, Putker M, van Zutphen IJ, Mauthe M, Zellmer S, Pals C, Verhagen LP, Groot Koerkamp MJ, Braat AK, Dansen TB, Holstege FC, Gebhardt R, Burgering BM, and Coffer PJ. Modulation of glutamine metabolism by the PI(3)K-PKB-FOXO network regulates autophagy. Nat Cell Biol 14: 829–837, 2012.
240.
Vaughn AE and Deshmukh M. Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. Nat Cell Biol 10: 1477–1483, 2008.
241.
Velu CS, Niture SK, Doneanu CE, Pattabiraman N, and Srivenugopal KS. Human p53 is inhibited by glutathionylation of cysteines present in the proximal DNA-binding domain during oxidative stress. Biochemistry 46: 7765–7780, 2007.
242.
Visscher M, Arkin MR, and Dansen TB. Covalent targeting of acquired cysteines in cancer. Curr Opin Chem Biol 30: 61–67, 2016.
243.
von Zglinicki T. Role of oxidative stress in telomere length regulation and replicative senescence. Ann N Y Acad Sci 908: 99–110, 2000.
244.
Vurusaner B, Poli G, and Basaga H. Tumor suppressor genes and ROS: complex networks of interactions. Free Radic Biol Med 52: 7–18, 2012.
245.
Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, Wilson KF, Ambrosio AL, Dias SM, Dang CV, and Cerione RA. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18: 207–219, 2010.
246.
Wang Y, Liu L, Pazhanisamy SK, Li H, Meng A, and Zhou D. Total body irradiation causes residual bone marrow injury by induction of persistent oxidative stress in murine hematopoietic stem cells. Free Radic Biol Med 48: 348–356, 2010.
247.
Wang Y, Yang J, and Yi J. Redox sensing by proteins: oxidative modifications on cysteines and the consequent events. Antioxid Redox Signal 16: 649–657, 2012.
248.
Wani R, Qian J, Yin L, Bechtold E, King SB, Poole LB, Paek E, Tsang AW, and Furdui CM. Isoform-specific regulation of Akt by PDGF-induced reactive oxygen species. Proc Natl Acad Sci U S A 108: 10550–10555, 2011.
249.
Warburg O. On respiratory impairment in cancer cells. Science 124: 269–270, 1956.
250.
Warburg O. On the origin of cancer cells. Science 123: 309–314, 1956.
251.
Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GR, and Chandel NS. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A 107: 8788–8793, 2010.
252.
Westphal D, Dewson G, Czabotar PE, and Kluck RM. Molecular biology of Bax and Bak activation and action. Biochim Biophys Acta 1813: 521–531, 2011.
253.
Wheeler MD, Smutney OM, and Samulski RJ. Secretion of extracellular superoxide dismutase from muscle transduced with recombinant adenovirus inhibits the growth of B16 melanomas in mice. Mol Cancer Res 1: 871–881, 2003.
254.
Winterbourn CC. Reconciling the chemistry and biology of reactive oxygen species. Nat Chem Biol 4: 278–286, 2008.
255.
Wondrak GT. Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal 11: 3013–3069, 2009.
256.
Xiong Y, Uys JD, Tew KD, and Townsend DM. S-glutathionylation: from molecular mechanisms to health outcomes. Antioxid Redox Signal 15: 233–270, 2011.
257.
Yalcin S, Zhang X, Luciano JP, Mungamuri SK, Marinkovic D, Vercherat C, Sarkar A, Grisotto M, Taneja R, and Ghaffari S. Foxo3 is essential for the regulation of ataxia telangiectasia mutated and oxidative stress-mediated homeostasis of hematopoietic stem cells. J Biol Chem 283: 25692–25705, 2008.
258.
Yamamoto T, Suzuki T, Kobayashi A, Wakabayashi J, Maher J, Motohashi H, and Yamamoto M. Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity. Mol Cell Biol 28: 2758–2770, 2008.
259.
Yang J, Gupta V, Carroll KS, and Liebler DC. Site-specific mapping and quantification of protein S-sulphenylation in cells. Nat Commun 5: 4776, 2014.
260.
Yeo H, Lyssiotis CA, Zhang Y, Ying H, Asara JM, Cantley LC, and Paik JH. FoxO3 coordinates metabolic pathways to maintain redox balance in neural stem cells. EMBO J 32: 2589–2602, 2013.
261.
Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff JL, Yan H, Wang W, Chen S, Viale A, Zheng H, Paik JH, Lim C, Guimaraes AR, Martin ES, Chang J, Hezel AF, Perry SR, Hu J, Gan B, Xiao Y, Asara JM, Weissleder R, Wang YA, Chin L, Cantley LC, and DePinho RA. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149: 656–670, 2012.
262.
Yoshida T, Goto S, Kawakatsu M, Urata Y, and Li TS. Mitochondrial dysfunction, a probable cause of persistent oxidative stress after exposure to ionizing radiation. Free Radic Res 46: 147–153, 2012.
263.
Zhang C, Liu J, Liang Y, Wu R, Zhao Y, Hong X, Lin M, Yu H, Liu L, Levine AJ, Hu W, and Feng Z. Tumour-associated mutant p53 drives the Warburg effect. Nat Commun 4: 2935, 2013.
264.
Zhang W, Shu XO, Li H, Yang G, Cai H, Ji BT, Gao J, Gao YT, Zheng W, and Xiang YB. Vitamin intake and liver cancer risk: a report from two cohort studies in China. J Natl Cancer Inst 104: 1173–1181, 2012.
265.
Zhu P, Tan MJ, Huang RL, Tan CK, Chong HC, Pal M, Lam CR, Boukamp P, Pan JY, Tan SH, Kersten S, Li HY, Ding JL, and Tan NS. Angiopoietin-like 4 protein elevates the prosurvival intracellular O2(-):H2O2 ratio and confers anoikis resistance to tumors. Cancer Cell 19: 401–415, 2011.
Information & Authors
Information
Published In
Antioxidants & Redox Signaling
Volume 25 • Issue Number 6 • August 20, 2016
Pages: 300 - 325
PubMed: 27353526
Copyright
Copyright 2016, Mary Ann Liebert, Inc.
History
Published in print: August 20, 2016
Published online: 20 August 2016
Published ahead of print: 2 August 2016
Published ahead of production: 28 June 2016
Accepted: 21 June 2016
Revision received: 10 June 2016
Received: 20 January 2016
Topics
Authors
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.